Search

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes

BI 764524: Sema3A antibody

Oxidase Inhibitor

BI 1291583: CatC Inhibitor

Modified yersinia

PD-1 antibody

BI 1569912

C3-binding polypeptide

Anti-fibrotic agent

Ion channel inhibitor

KRAS multi-inhibitor

Immunomodulator

NPY2r agonist

BI 765845: Heart disease modulator | Myocardial infarction

IL11 antibody

Lysophospholipase inhibitor

12th Expert Forum on Farm Animal Well-Being

The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts

Algorithms to battle heartworm disease

Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets

Boehringer Ingelheim Venture Fund invests precision antimicrobials

Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials

Breathing hope: fighting the lung disease pulmonary fibrosis

The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.

BI 1358894 - PTSD

BI 1358894

European_Commission_approves_nintedanibSSc-ILD

Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Boehringer Ingelheim and Fraunhofer partnership

Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products

New production center for Veterinary Public Health

Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers